We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Protein Biomarkers Aid Detection of Prodromal Alzheimer Disease

By LabMedica International staff writers
Posted on 17 Jan 2012
Cerebrospinal fluid (CSF) biomarkers can predict future development of Alzheimer Disease (AD) dementia within 10 years in patients with mild cognitive impairment (MCI). More...


The CSF biomarkers, total tau (T-tau), phosphorylated tau (P-tau), and β-amyloid 1-42 (Aβ42), have been compared for their ability to distinguish between early and late converters to AD.

Scientists at Skåne University (Malmö; Sweden) carried out an extended follow-up of the cohort from a previous study involving 137 patients with mild cognitive impairment (MCI) at baseline for an average follow-up period of 9.2 years. Lumbar punctures were performed at base line and during follow up on the 137 patients and 39 human volunteers. They analyzed CSF concentrations of Aβ42, T-tau, and phosphorylated tau P-tau181 using xMAP technology.

Systems using xMAP technology (Luminex; Austin, TX, USA) perform discrete bioassays on the surface of color-coded beads known as microspheres, which are then read in a compact analyzer. The results of the study showed an equal reduction in baseline CSF Aβ42 levels in patients with MCI who converted to AD within five years, the early converters, compared with those who converted later, such as between five and 10 years, whilst T-tau and P-tau levels were substantially higher in early converters compared to later ones. As many as 91% of the patients with mild memory impairment who had these risk markers went on to develop Alzheimer's within a ten-year period. In contrast, those who had memory impairment but normal values for the markers did not run a higher risk of getting Alzheimer's than healthy individuals

By observing how the levels of the biomarkers develop over the ten years before the patient's diagnosis, the scientists have also been able to map the progression of the disease in the brain. The results indicate that it starts with a modified turnover of beta-amyloid. Only later is this followed by changes in the tau protein and damage to nerve cells. This can be important information for those developing new therapies for Alzheimer's. Senior author of the study Oskar Hansson, MD, PhD, said, "This is a very important finding with regard to the development of new therapies against the disease. All prospective therapies have so far shown to be ineffective in stopping the disease, and many people are concerned that the pharmaceutical companies will give up their efforts in this field." The study was published in the January 2012 edition of the Archives of General Psychiatry.

Related Links:

Skåne University
Luminex



New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
New
Rapid Molecular Testing Device
FlashDetect Flash10
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The 3D paper-based analytical device has shown high clinical accuracy for adult-onset immunodeficiency (Photo courtesy of National Taiwan University)

Paper-Based Device Accurately Detects Immune Defects in 10 Minutes

Patients with hidden immune defects are especially vulnerable to severe and persistent infections, often due to autoantibodies that block interferon-gamma (IFN-γ), a key molecule in immune defense.... Read more

Microbiology

view channel
Image: The groundbreaking salmonella antimicrobial resistance prediction platform has demonstrated 95% accuracy (Photo courtesy of Yujie You et al., DOI: 10.1016/j.eng.2025.01.013)

New Platform Leverages AI and Quantum Computing to Predict Salmonella Antimicrobial Resistance

Antimicrobial-resistant Salmonella strains are a growing public health concern due to the overuse of antimicrobials and the rise of genetic mutations. Accurate prediction of resistance is crucial for effective... Read more

Technology

view channel
Image: The Check4 gene-detection platform (Photo courtesy of IdentifySensors)

Electronic Biosensors Used to Detect Pathogens Can Rapidly Detect Cancer Cells

A major challenge in healthcare is the early and affordable detection of serious diseases such as cancer. Early diagnosis remains difficult due to the complexity of identifying specific genetic markers... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.